Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
VSTM
vs
S&P 500
VSTM
S&P 500
Over the past 12 months, VSTM has underperformed S&P 500, delivering a return of -12% compared to S&P 500's +17% growth.
Stocks Performance
VSTM vs S&P 500
Performance Gap
VSTM vs S&P 500
Performance By Year
VSTM vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Verastem Inc
Glance View
Verastem is a biotechnology company focused on cancer drugs, especially medicines that target tumors driven by the RAS/MAPK signaling pathway. Its main work is to develop, test, and bring to market prescription therapies for hard-to-treat cancers, with a strong emphasis on ovarian cancer and other solid tumors. In simple terms, it is a drug maker, not a hospital or a research tools company. The company sells its treatments through the medical system, so its main customers are oncologists, cancer centers, hospitals, and the pharmacies and payers that support patient access. Verastem makes money mainly from sales of approved drugs, and it can also earn income from collaboration, licensing, or development agreements tied to its drug pipeline. Because it is a biotech company, a big part of its value comes from whether its clinical programs lead to approved medicines that doctors can prescribe. What makes Verastem different is its narrow focus on a specific cancer biology pathway and on combination therapies, rather than on a broad range of medicines. That gives it a specialized role in the oncology market: it tries to find patient groups that may respond better to targeted treatment and then commercialize those therapies through the standard drug distribution and reimbursement system.
